Trimetazidine Induces Parkinsonism, Gait Disorders and Tremor
Thérapie, 60 4 (2005) 419-422
Published online: 2007-03-01
Articles citing this article
The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).
Cited article:
This article has been cited by the following article(s):
Long-term thiethylperazine treatment in the Tg4-42 mouse model of Alzheimer's disease mouse: Therapeutic potential vs. adverse effects
Lisa Katharina Ruoff, Irina Wanda Helene Bänfer, Djavid Elias Liedtke, Sofie Elena China, Jens Wiltfang, Thomas A. Bayer, Sören Frederik Bock, Friederike Spandau, Caroline Bouter, Nicola Beindorff and Yvonne BouterPharmacology Biochemistry and Behavior 258 174127 (2026)
https://doi.org/10.1016/j.pbb.2025.174127
1097 (2025)
https://doi.org/10.1007/978-3-031-94841-1_246
Evaluation of the Pharmacokinetics, Bioequivalence, and Safety of Two Preparations of 20‐mg Trimetazidine in Healthy Chinese Subjects
Dongmei Tan, Fucai Zhang, Xihua Fu, Jianfen Su, Zuoheng Xu, Hui Yang and Yanping MuClinical Pharmacology in Drug Development 14 (11) 889 (2025)
https://doi.org/10.1002/cpdd.1582
Neurochemical aspects of the cardiotropic compound ALM-802S pharmacological activity
I. B. Tsorin, L. G. Kolik, M. B. Vititnova, V. V. Barchukov, G. V. Mokrov, V. S. Kudrin and S. A. KryzhanovskyPharmacokinetics and Pharmacodynamics (3) 39 (2025)
https://doi.org/10.37489/2587-7836-2025-3-39-46
Trimetazidine Use in Cardiovascular Disease
Mohammed Kallash and William H. FrishmanCardiology in Review (2025)
https://doi.org/10.1097/CRD.0000000000000862
No fault or negligence after an adverse analytical finding due to a contaminated supplement: mission impossible. Two examples involving trimetazidine
Pascal KintzClinical Chemistry and Laboratory Medicine (CCLM) 63 (11) 2171 (2025)
https://doi.org/10.1515/cclm-2025-0549
Interest of hair tests to discriminate a tail end of a doping regimen from a possible contamination in case of challenging an anti‐doping rule violation. V. Case reports involving trimetazidine, a drug where the concentration after a single 20 mg dose has been established
Pascal Kintz, Alice Ameline and Laurie GheddarDrug Testing and Analysis 17 (6) 779 (2025)
https://doi.org/10.1002/dta.3775
(2024)
https://doi.org/10.21203/rs.3.rs-3964503/v1
(2022)
https://doi.org/10.1101/2022.05.09.22274810
Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study
Zhu Min, Liu Xuelu, Zhang Ran, Shu Qiuhong and Meng YongAdvances in Therapy 39 (12) 5514 (2022)
https://doi.org/10.1007/s12325-022-02315-x
Trimetazidine Use in Parkinson’s Disease: Is It a Resolved Problem?
Dávid Pintér, Dániel Bereczki, András Ajtay, Ferenc Oberfrank, József Janszky and Norbert Kovácseneuro 8 (3) ENEURO.0452-20.2021 (2021)
https://doi.org/10.1523/ENEURO.0452-20.2021
The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review
Eduard Bezuglov, Oleg Talibov, Mikhail Butovskiy, et al.Asian Journal of Sports Medicine 12 (2) (2021)
https://doi.org/10.5812/asjsm.110753
Cinnarizine- and flunarizine-associated movement disorder: a literature review
Jamir Pitton Rissardo and Ana Letícia Fornari CapraraThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery 56 (1) (2020)
https://doi.org/10.1186/s41983-020-00197-w
Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study
Seungyeon Kim, Yun Mi Yu, Jeongyoon Kwon, Kyeong Hye Jeong, Jeong Sang Lee and Euni LeeInternational Journal of Environmental Research and Public Health 17 (19) 7256 (2020)
https://doi.org/10.3390/ijerph17197256
Trimetazidine-Induced Parkinsonism: A Systematic Review
Anna Marielle B. Dy, Lorenzo Luis G. Limjoco and Roland Dominic G. JamoraFrontiers in Neurology 11 (2020)
https://doi.org/10.3389/fneur.2020.00044
La trimétazidine (Vastarel) est-elle un produit dopant ? Proposition pour une suppression de la liste des produits interdits de l’Agence mondiale anti-dopage
Pascal KintzToxicologie Analytique et Clinique 32 (4) 239 (2020)
https://doi.org/10.1016/j.toxac.2020.09.079
The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease
Dávid Pintér, Annamária Juhász, Márk Harmat, József Janszky and Norbert KovácsScientific Reports 10 (1) (2020)
https://doi.org/10.1038/s41598-020-66692-5
Trimetazidine and parkinsonism: A prospective study
Dávid Pintér, Márton Kovács, Márk Harmat, Annamária Juhász, József Janszky and Norbert KovácsParkinsonism & Related Disorders 62 117 (2019)
https://doi.org/10.1016/j.parkreldis.2019.01.005
Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease
Yilin Tang, Ke Yang, Jue Zhao, Xiaoniu Liang and Jian WangACS Chemical Neuroscience 10 (2) 954 (2019)
https://doi.org/10.1021/acschemneuro.8b00456
Extra energy for hearts with a genetic defect: ENERGY trial
B. O. van Driel, A. C. van Rossum, M. Michels, R. Huurman and J. van der VeldenNetherlands Heart Journal 27 (4) 200 (2019)
https://doi.org/10.1007/s12471-019-1239-0
Cardiac metabolism — A promising therapeutic target for heart failure
Hannah Noordali, Brodie L. Loudon, Michael P. Frenneaux and Melanie MadhaniPharmacology & Therapeutics 182 95 (2018)
https://doi.org/10.1016/j.pharmthera.2017.08.001
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010–2015)
Aastha Singh, Abhishek Singh and Dwaipayan SenStem Cell Research & Therapy 7 (1) (2016)
https://doi.org/10.1186/s13287-016-0341-0
Trimetazidine in Practice
Csaba A. DézsiAmerican Journal of Therapeutics 23 (3) e871 (2016)
https://doi.org/10.1097/MJT.0000000000000180
Respuesta a Idaptan® (trimetazidina): la panacea
Carmelo Aguirre, Montserrat García García and Ainhoa Etxebarria AretxagaAtención Primaria 46 (1) 51 (2014)
https://doi.org/10.1016/j.aprim.2013.04.011
Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease
Piotr Chrusciel, Jacek Rysz and Maciej BanachDrugs 74 (9) 971 (2014)
https://doi.org/10.1007/s40265-014-0233-5
The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration
Anna Jarek, Marzena Wójtowicz, Dorota Kwiatkowska, Monika Kita, Ewa Turek‐Lepa, Katarzyna Chajewska, Sylwia Lewandowska‐Pachecka and Andrzej PokrywkaDrug Testing and Analysis 6 (11-12) 1191 (2014)
https://doi.org/10.1002/dta.1755
Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches
Gerd Sigmund, Anja Koch, Anne‐Katrin Orlovius, Sven Guddat, Andreas Thomas, Wilhelm Schänzer and Mario ThevisDrug Testing and Analysis 6 (11-12) 1197 (2014)
https://doi.org/10.1002/dta.1680
38 (2013)
https://doi.org/10.1016/B978-1-4557-3322-4.00011-9
Diagnostic accuracy of 123I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study
J. Olivares Romero and A. Arjona PadilloNeurología (English Edition) 28 (5) 276 (2013)
https://doi.org/10.1016/j.nrleng.2012.05.007
Antipsychotic‐Like Effect of Trimetazidine in a Rodent Model
Oytun Erbaş, Hüseyin Serdar Akseki, Betül Eliküçük, Dilek Taşkıran, N. Berretta, J. L. Labandeira-García, A. Takano and Y. YoshiyamaThe Scientific World Journal 2013 (1) (2013)
https://doi.org/10.1155/2013/686304
Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo
J. Olivares Romero and A. Arjona PadilloNeurología 28 (5) 276 (2013)
https://doi.org/10.1016/j.nrl.2012.05.005
Drug-induced parkinsonism
José López-Sendón, Maria A Mena and Justo G de YébenesExpert Opinion on Drug Safety 12 (4) 487 (2013)
https://doi.org/10.1517/14740338.2013.787065
Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
Marina Bayeva, Konrad Teodor Sawicki and Hossein ArdehaliJournal of the American Heart Association 2 (6) (2013)
https://doi.org/10.1161/JAHA.113.000433
Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases
Kamel Masmoudi, Henri Masson, Valérie Gras and Michel AndréjakFundamental & Clinical Pharmacology 26 (2) 198 (2012)
https://doi.org/10.1111/j.1472-8206.2011.01008.x
Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
Emmanuelle Bondon‐Guitton, Santiago Perez‐Lloret, Haleh Bagheri, Christine Brefel, Olivier Rascol and Jean‐Louis MontastrucMovement Disorders 26 (12) 2226 (2011)
https://doi.org/10.1002/mds.23828
99 (2011)
https://doi.org/10.1017/CBO9780511920936.007
Encéphalopathie avec mouvements choréiformes induits par la trimétazidine : à propos d’un cas
J. Sivet, B. de la Gastine, B. Mosquet, et al.La Revue de Médecine Interne 29 (6) 512 (2008)
https://doi.org/10.1016/j.revmed.2007.12.001
Trimetazidine Revisited: A Comprehensive Review of the Pharmacological Effects and Analytical Techniques for the Determination of Trimetazidine
A. Onay‐Besikci and S.A. ÖzkanCardiovascular Therapeutics 26 (2) 147 (2008)
https://doi.org/10.1111/j.1527-3466.2008.00043.x
Drug-Induced Parkinsonism in the Elderly
Kelvin L Chou and Joseph H FriedmanFuture Neurology 2 (3) 307 (2007)
https://doi.org/10.2217/14796708.2.3.307
Structure–activity studies on the protection of Trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia–reperfusion injury
Tamás Kálai, Mahmood Khan, Mária Balog, Vijay Kumar Kutala, Periannan Kuppusamy and Kálmán HidegBioorganic & Medicinal Chemistry 14 (16) 5510 (2006)
https://doi.org/10.1016/j.bmc.2006.04.040
Drug-induced parkinsonism
Maria A Mena and Justo G de YébenesExpert Opinion on Drug Safety 5 (6) 759 (2006)
https://doi.org/10.1517/14740338.5.6.759